CO2018012941A2 - Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos - Google Patents

Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos

Info

Publication number
CO2018012941A2
CO2018012941A2 CONC2018/0012941A CO2018012941A CO2018012941A2 CO 2018012941 A2 CO2018012941 A2 CO 2018012941A2 CO 2018012941 A CO2018012941 A CO 2018012941A CO 2018012941 A2 CO2018012941 A2 CO 2018012941A2
Authority
CO
Colombia
Prior art keywords
benzoimidazol
diethylamino
acrylamide
hydroxy
butyl
Prior art date
Application number
CONC2018/0012941A
Other languages
English (en)
Inventor
David Duncan
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CO2018012941A2 publication Critical patent/CO2018012941A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen Polimorfos de Formas cristalinas del 3-[2-butil-1-(2-dietilamino-etil)-1H-benzoimidazol-5-il]-N-hidroxi-acrilamida. También se presentan composiciones farmacéuticas y los usos de las mismas, Formas compuestas y composiciones, para el tratamiento de enfermedades y afecciones.
CONC2018/0012941A 2016-05-02 2018-11-29 Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos CO2018012941A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662330673P 2016-05-02 2016-05-02
PCT/US2017/030414 WO2017192451A1 (en) 2016-05-02 2017-05-01 Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof

Publications (1)

Publication Number Publication Date
CO2018012941A2 true CO2018012941A2 (es) 2018-12-28

Family

ID=60203321

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0012941A CO2018012941A2 (es) 2016-05-02 2018-11-29 Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos

Country Status (20)

Country Link
US (2) US10626092B2 (es)
EP (2) EP3939966A1 (es)
JP (1) JP2019514905A (es)
KR (1) KR20190005904A (es)
CN (1) CN109414425A (es)
AR (1) AR108257A1 (es)
AU (1) AU2017261218A1 (es)
BR (1) BR112018072439A2 (es)
CA (1) CA3022011A1 (es)
CL (1) CL2018003109A1 (es)
CO (1) CO2018012941A2 (es)
EA (1) EA201892341A1 (es)
ES (1) ES2886495T3 (es)
IL (1) IL262578A (es)
MA (1) MA44880A (es)
MX (1) MX2018013349A (es)
PH (1) PH12018502296A1 (es)
SG (1) SG11201809471UA (es)
TW (1) TW201741286A (es)
WO (1) WO2017192451A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157742A1 (zh) * 2017-02-28 2018-09-07 苏州科睿思制药有限公司 Sb-939的盐的晶型及其制备方法和用途
WO2019126282A1 (en) 2017-12-19 2019-06-27 Assia Chemical Industries Ltd. Crystalline polymorphs of pracinostat and pracinostat salts
WO2019149262A1 (zh) * 2018-02-05 2019-08-08 苏州科睿思制药有限公司 Sb-939的晶型及其制备方法和用途
WO2021217180A1 (en) 2020-04-22 2021-10-28 Johnson Matthey Public Limited Company Novel forms of pracinostat dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2291749A1 (fr) 1974-11-20 1976-06-18 Delalande Sa Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique
ATE198601T1 (de) 1992-05-20 2001-01-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
ATE302193T1 (de) 1999-01-13 2005-09-15 Warner Lambert Co Benzoheterozyklen und ihre verwendung als mek inhibitoren
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
ATE250932T1 (de) 1999-07-16 2003-10-15 Warner Lambert Co Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
ID30204A (id) 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP2005517007A (ja) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
UA76837C2 (uk) 2002-03-13 2006-09-15 Еррей Байофарма Інк. N3 алкіловані похідні бензімідазолу як інгібітори мек
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CN1659161A (zh) 2002-04-16 2005-08-24 帝人株式会社 具有ccr3拮抗作用的哌啶衍生物
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
JP5042626B2 (ja) 2003-09-22 2012-10-03 エス＊バイオ プライベート リミティッド ベンズイミダゾール誘導体：製造及び医薬適用
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
WO2007030080A1 (en) 2005-09-08 2007-03-15 S*Bio Pte Ltd Heterocyclic compounds
AU2006201177B2 (en) * 2005-09-08 2012-06-14 Mei Pharma, Inc. Heterocyclic compounds
EP2131840B1 (en) 2007-03-07 2018-10-17 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
EP2914254B1 (en) 2012-10-30 2020-01-08 MEI Pharma, Inc. Combination therapies to treat chemoresistant cancers

Also Published As

Publication number Publication date
MA44880A (fr) 2021-03-17
EP3939966A1 (en) 2022-01-19
BR112018072439A2 (pt) 2019-02-19
SG11201809471UA (en) 2018-11-29
PH12018502296B1 (en) 2019-07-08
WO2017192451A1 (en) 2017-11-09
PH12018502296A1 (en) 2019-07-08
JP2019514905A (ja) 2019-06-06
US10626092B2 (en) 2020-04-21
AU2017261218A1 (en) 2018-11-29
KR20190005904A (ko) 2019-01-16
AR108257A1 (es) 2018-08-01
US20200317621A1 (en) 2020-10-08
EP3452035A4 (en) 2019-09-25
IL262578A (en) 2018-12-31
MX2018013349A (es) 2019-02-20
EA201892341A1 (ru) 2019-05-31
ES2886495T3 (es) 2021-12-20
US20190152923A1 (en) 2019-05-23
CL2018003109A1 (es) 2019-04-26
CA3022011A1 (en) 2017-11-09
TW201741286A (zh) 2017-12-01
CN109414425A (zh) 2019-03-01
EP3452035A1 (en) 2019-03-13
EP3452035B1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018012941A2 (es) Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
CO2017001884A2 (es) Polimorfos de selinexor
ECSP17073743A (es) Moduladores de k-ras
DOP2016000271A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
DOP2018000040A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
ES2965883T3 (es) Composición oftálmica para el tratamiento de la enfermedad del ojo seco
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
ECSP18012103A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
UY36221A (es) Derivados de isoindolinona
CR20170005A (es) Derivados de insoindolina
CL2018001085A1 (es) Derivados de indolin-2-ona
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos